MG-132
注:本產(chǎn)品僅用于科研,不可用于臨床
生物活性
Z-Leu-Leu-Leu-al is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis
IC50 & Target
IC50: 100 nM (Proteasome), 1.2 μM (Calpain)
體外研究(In Vitro)
MG-132 (Z-Leu-Leu-Leu-al) initiates neurite outgrowth in PC12 cells at a low concentration (30 nM) and is a very strong inhibitor of 20S proteasome[3].
MG-132 (10 μM; 1 hour) reverses the effects of TNF- α on I κ B degradation and NF-κ B activation in A549 cells[4].
MG-132 (0.75-5 μM; 24 hours) potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition[5].
MG-132 (10-40 μM; 24 hours) significantly reduces the viability of C6 glioma cells in both time- and concentration-dependent manners and shows the IC50 of 18.5 μM at 24 hours[6].
MG-132 (18.5 μM; 24 hours) induces down-regulation of anti-apoptotic proteins Bcl-2 and XIAP and up-regulates expression of pro-apoptotic protein Bax and caspase-3[6].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
體內(nèi)研究(In Vivo)
MG132 (10 mg/kg; i.p.; daily for 25 days starting 5 days after EC9706 cells injection) significantly inhibits tumor growth of the EC9706 xenograft without causing toxicity to mice[7].
MG-132 (1 mg/kg; i.v.; twice a week for 4 weeks) shows potent tumor inhibitory effect against mice bearing HeLa tumors[8].
MG-132 (1-10 μg/kg/24 hours; subcutaneously implanted osmotic pumps; for 8 days) greatly increases the expression levels of β-dystroglycan, α-dystroglycan, α-sarcoglycan, and dystrophin in skeletal muscle lysates in mice (six-month-old male C57BL/10ScSn DMD mdx mice)[9].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 5- to 6-weeks old female athymic nude mice (EC9706 xenograft) |
| Dosage: | 10 mg/kg |
| Administration: | I.p.; daily for 25 days starting 5 days after EC9706 cells injection |
| Result: | Significantly inhibited tumor growth of the EC9706 xenograft without causing toxicity to the mice. |
分子量
475.62
性狀
Solid
Formula
C26H41N3O5
CAS 號(hào)
133407-82-6
運(yùn)輸條件
Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式
| Powder | -20°C | 3 years |
|---|
| In solvent | -80°C | 6 months |
|---|
| -20°C | 1 month |
|---|
溶解性數(shù)據(jù)
DMSO : 100 mg/mL (210.25 mM; Need ultrasonic)
配制儲(chǔ)備液
| 濃度溶劑體積質(zhì)量 | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1025 mL | 10.5126 mL | 21.0252 mL |
| 5 mM | 0.4205 mL | 2.1025 mL | 4.2050 mL |
| 10 mM | 0.2103 mL | 1.0513 mL | 2.1025 mL |
*請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?6 個(gè)月內(nèi)使用,-20°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?1 個(gè)月內(nèi)使用。
In Vivo:
請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨?。以下溶解方案都?qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用; 以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶
1.
請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.67 mg/mL (3.51 mM); Clear solution
2.
請(qǐng)依序添加每種溶劑: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 1.67 mg/mL (3.51 mM); Suspended solution; Need ultrasonic
3.
請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oil
Solubility: ≥ 1.67 mg/mL (3.51 mM); Clear solution
用戶評(píng)論
發(fā)布評(píng)論